|Dr. Michael E. Castagna||CEO & Director||675.7k||N/A||1977|
|Mr. Steven B. Binder||Chief Financial Officer||520.45k||N/A||1963|
|Dr. David B. Thomson||Exec. VP, Gen. Counsel & Sec.||581.28k||N/A||1967|
|Mr. James Patrick McCauley Jr., J.D., M.B.A.||Chief Commercial Officer||731.64k||N/A||1966|
|Dr. David M. Kendall M.D.||Chief Medical Officer||685.23k||N/A||1962|
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
MannKind Corporation’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 4; Compensation: 9.